BO-264 |
| Katalog-Nr.GC39483 |
BO-264 ist ein hochwirksamer und oral aktiver Transforming Acidic Coiled-Coil 3 (TACC3)-Inhibitor mit einem IC50 von 188 nM und einem Kd von 1,5 nM. BO-264 blockiert spezifisch die Funktion des FGFR3-TACC3-Fusionsproteins. BO-264 induziert Spindel Assembly Checkpoint (SAC)-abhÄngigen mitotischen Arrest, DNA-SchÄden und Apoptose. BO-264 hat ein breites Spektrum an AntitumoraktivitÄt.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2408648-20-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
BO-264 is a highly potent and orally active transforming acidic coiled-coil 3 (TACC3) inhibitor with an IC50 of 188 nM and a Kd of 1.5 nM. BO-264 specifically blocks the function of FGFR3-TACC3 fusion protein. BO-264 induces spindle assembly checkpoint (SAC)-dependent mitotic arrest, DNA damage and apoptosis. BO-264 has broad-spectrum antitumor activity[1].
[1]. Akbulut O, et al. A Highly Potent TACC3 Inhibitor as a Novel Anti-cancer Drug Candidate. Mol Cancer Ther. 2020 Mar 26. pii: molcanther.0957.2019.
Average Rating: 5 (Based on Reviews and 19 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *